New Myelodysplastic Syndromes Study Results Reported from Rochester General Hospital (Outcomes and Trends of Allogenic Hematopoietic Stem Cell Transplant Among MDS Patients- NIS 2016-2020).

Researchers from Rochester General Hospital conducted a study analyzing outcomes and trends of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with Myelodysplastic Syndromes (MDS) using data from the National Inpatient Sample (NIS) from 2016 to 2020. The study found that MDS patients undergoing HSCT were older and had a higher burden of comorbidities compared to non-MDS patients. Despite advancements in supportive care, MDS patients experienced higher in-hospital mortality and complications such as mechanical ventilation and neutropenic fever. The study also noted a steady increase in the proportion of allogeneic HSCT performed on MDS patients from 2016 to 2019, with a slight decline in 2020 possibly due to the COVID-19 pandemic. [Extracted from the article]